Lucas Saposnik

Consejo Nacional de Investigaciones Científicas y Técnicas — Argentina

Medicine · Health Sciences

4h-index65citations13works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(9), Immunotherapy and Immune Responses(3), Animal Virus Infections Studies(3), COVID-19 Clinical Research Studies(2), Vaccine Coverage and Hesitancy(2)

Publications13 total

Zinc starvation uncovers bacterial host-specific proteases that shape NDM adaptability in <i>Acinetobacter baumannii</i>
mBio·2025Open Access
Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity
npj Vaccines·2025· 3 citedOpen Access
Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial
Vaccine·2025· 2 citedOpen Access
Ecotin protects Salmonella Typhimurium against the microbicidal activity of host proteases
PLoS Pathogens·2025· 2 citedOpen Access
Ecotin protects <i>Salmonella</i> Typhimurium against the microbicidal activity of host proteases
2024Open Access
Immunogenicity and Safety of Gamma, Omicron BA.4/5 and Bivalent SARS-CoV-2 RBD-based Protein Booster Vaccines in Adults Previously Immunized with Different Vaccine Platforms: a Phase II/III, Randomized, Clinical Trial
2024Open Access
A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
Nature Communications·2024· 10 citedOpen Access
Regulation of human neutrophil IL-1β secretion induced by Escherichia coli O157:H7 responsible for hemolytic uremic syndrome
PLoS Pathogens·2023· 5 citedOpen Access
Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
Nature Communications·2023· 14 citedOpen Access
Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report
2023· 4 citedOpen Access
A Gamma-adapted recombinant subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
2023· 3 citedOpen Access
A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice
Frontiers in Immunology·2022· 20 citedOpen Access
A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection
2021· 2 citedOpen Access

Frequent Co-authors

Juliana Cassataro(13), Lorena M. Coria(11), Karina A. Pasquevich(11), Laura Bruno(10), Celeste Pueblas Castro(9), Juan M. Corchado(7), Agostina Demaría(7), Julio C. Vega(7), Juan Fló(7), Melina Salvatori(6), Diego E. Álvarez(5), Ana Ceballos(5), Lineia Prado(5), Eliana F. Castro(4), William B. Stone(4), Augusto Varese(4), Albert J. Auguste(4), Jorge Geffner(4), Sabrina A. Del Priore(4), Andrés C. Hernando Insua(4)